SLGL
NASDAQ HealthcareSol-Gel Technologies Ltd. - Ordinary Shares
Biotechnology
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
๐ Market Data
| Price | $78.08 |
|---|---|
| Volume | 101,921 |
| Market Cap | 253.39M |
| Beta | 1.130 |
| RSI (14-Day) | 62.0 |
| 200-Day MA | $61.56 |
| 50-Day MA | $73.12 |
| 52-Week High | $97.97 |
| 52-Week Low | $8.00 |
| Forward P/E | -8.48 |
| Price / Book | 4.97 |
๐ฏ Investment Strategy Scores
SLGL scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (65/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (5/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find SLGL in your text
Paste any article, transcript, or post โ the tool will extract SLGL and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.